Skip to main content
Journal of Patient-Reported Outcomes

Table 4 Multivariate regression analyses measuring associations among pediatric quality of life (PedsQL) and disease activity/symptoms and treatment burden (N = 180)

From: Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis

  PedsQL total score PedsQL psychosocial score PedsQL physical score
β (S.E.) p-value β (S.E.) p-value β (S.E.) p-value
Model 1a-1d Individual PROs
 1a) Pain interferencea −1.30 (0.05) < 0.0001 −1.17 (0.04) < 0.0001 −1.53 (0.10) < 0.0001
 1b) Morning stiffness
  >15 min −19.92 (0.91) < 0.0001 −16.77 (1.23) < 0.0001 −25.65 (2.05) < 0.0001
  ≤ 15 min reference reference reference
 1c) Serious medication side effect
  Any −12.54 (3.77) 0.0009 −10.82 (3.54) 0.0023 −15.68 (4.75) 0.0010
  None reference reference reference
 1d) Methotrexate status
  With methotrexate intolerance −3.66 (1.42) 0.0100 −3.96 (0.77) < 0.0001 −3.15 (3.20) 0.3239
  On methotrexate without intolerance 4.89 (1.24) < 0.0001 4.84 (1.43) 0.0007 4.91 (2.49) 0.0487
  Not on methotrexate reference reference reference
Model 2 Disease Burden PROs
 Pain interferencea −1.27 (0.05) < 0.0001 −1.17 (0.05) < 0.0001 −1.45 (0.09) < 0.0001
 Morning stiffness
  >15 min −1.99 (0.50) < 0.0001 −0.28 (0.92) 0.7611 −5.13 (1.81) 0.0046
  ≤ 15 min reference reference reference
Model 3 Treatment Burden PROs
 Serious medication side effect
  Any −11.68 (3.77) 0.0020 −9.87 (3.70) 0.0076 −15.10 (4.56) 0.0009
  None reference reference reference
 Methotrexate status
  With methotrexate intolerance −2.13 (1.34) 0.1121 −2.66 (0.30) < 0.0001 −1.15 (3.46) 0.7406
  On methotrexate without intolerance 3.89 (1.64) 0.0175 4.01 (2.14) 0.0607 3.73 (1.67) 0.0257
  Not on methotrexate reference reference reference
Model 4 All PROs
 Pain interferencea −1.21 (0.07) < 0.0001 −1.12 (0.07) < 0.0001 −1.38 (0.08) < 0.0001
 Morning stiffness
  >15 min −2.39 (0.17) < 0.0001 −0.73 (0.80) 0.3628 −5.48 (1.88) 0.0035
  ≤ 15 min reference reference reference
 Serious medication side effect
  Any −3.64 (1.89) 0.0548 −2.67 (2.18) 0.2201 −5.47 (2.28) 0.0163
  None reference reference reference
Methotrexate status
  With methotrexate intolerance −3.24 (0.92) 0.0004 −3.57 (1.06) 0.0008 −2.55 (2.48) 0.3031
  On methotrexate without intolerance 1.47 (0.39) 0.0001 1.83 (0.73) 0.0119 0.94 (2.11) 0.6540
  Not on methotrexate reference reference reference
  1. All estimates were obtained using generalized estimating equations (GEE) to account for clustering within clinics and were adjusted for demographics including age (continuous), sex, race/ethnicity, parent education, and disease duration (continuous); regression coefficients (β) and their standard errors (SE) are presented
  2. Model 1a-1d assessed association between PedsQL score and each individual PRO
  3. Model 2 assessed association between PedsQL score and both of the disease burden PROs
  4. Model 3 assessed association between PedsQL score and both of the treatment burden PROs
  5. Model 4 included all PROs simultaneously
  6. aCoefficients represent the change in PedsQL score for a one unit change in the transformed pain interference score (T-score)
Back to article page